| |
|
|
|
|
|
 |
| |
|
È®Åõ¿¬°í FAKTU OINT.[Albotyl , Dibucaine HCl]
|
|
ÀϹÝÀǾàǰ | »èÁ¦
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
670001270[A02302651]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1g(2007.01.01)(ÇöÀç¾à°¡)
\121 ¿ø/1g(2000.07.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Æ÷À塤À¯Åë´ÜÀ§ |
30g
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
´ÙÀ½ °æ¿ìÀÇ ÀϽÃÀû ¿ÏÈ : Ä¡¿, Ä¡ÇÙ, °¡·Á¿ò, Ä¡ÃâÇ÷, Ç×¹®ÁÖÀ§¿°, Ç×¹®½ÀÁø
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:338600COM ¿¡ µû¸¥ ½É»çÁöħ¿¶÷]
1ÀÏ 2-3ȸ Àû´ç·®À» ȯºÎ¿¡ ¹Ù¸¥´Ù.
[Á¦Çüº°º¹¾àÁöµµ]
|
| ±Ý±â |
- Áö±Ý±îÁö ÀÌ ¾à¿¡ ÀÇÇÑ ¹ßÁø, ¹ßÀû, °¡·Á¿ò µîÀ» ÀÏÀ¸Å² ÀûÀÌ Àִ ȯÀÚ
- µðºÎÄ«ÀÎ ¹× ´Ù¸¥ ¾Æ¹Ìµå°è ±¹¼Ò¸¶ÃëÁ¦¿¡ °ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ
|
| ½ÅÁßÅõ¿© |
Áö±Ý±îÁö ¾à¿¡ ÀÇÇÑ ¹ßÁø, ¹ßÀû, °¡·Á¿òµîÀ» ÀÏÀ¸Å² ÀÏÀÌ ÀÖ´Â »ç¶÷. |
| ÀÌ»ó¹ÝÀÀ |
- ¶§¶§·Î ÀϽÃÀûÀÎ ÀÛ¿°¨À̳ª °¡·Á¿òÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸³ª °ð ¼Ò½ÇµÈ´Ù.
- Ư¼öÇÑ °æ¿ì¿¡ ¾Ë·¹¸£±â¼º °ú¹Î¹ÝÀÀÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç, °¡·Á¿ò°ú ±¸ÁøÀ» µ¿¹ÝÇÏ´Â È«¹ÝÀÌ »ý±æ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ °æ¿ì Ä¡·á¸¦ ÁßÁöÇÑ´Ù.
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Dibucaine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Local anesthetics block both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions. This reversibly stabilizes the membrane and inhibits depolarization, resulting in the failure of a propagated action potential and subsequent conduction blockade.
|
| Pharmacology |
Dibucaine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Dibucaine is an amide-type local anesthetic, similar to lidocaine.
|
| Metabolism |
Dibucaine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 1A2 (CYP1A2)Cytochrome P450 2D6 (CYP2D6)Cholinesterase
|
| Protein Binding |
Dibucaine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
|
| Half-life |
Dibucaine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
|
| Absorption |
Dibucaine¿¡ ´ëÇÑ Absorption Á¤º¸ In general, ionized forms (salts) of local anesthetics are not readily absorbed through intact skin. However, both nonionized (bases) and ionized forms of local anesthetics are readily absorbed through traumatized or abraded skin into the systemic circulation.
|
| Pharmacokinetics |
Dibucaine HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÛ¿ë¹ßÇö½Ã°£ : 15ºÐ À̳»
- ÀÛ¿ëÁö¼Ó½Ã°£ : 2-4 ½Ã°£
- Èí¼ö : ¼Õ»óµÇÁö ¾ÊÀº ÇǺο¡ Àû¿ë½Ã Èí¼ö´Â ¸Å¿ì ÀûÁö¸¸, Á¡¸·À̳ª ¼Õ»óµÈ ÇǺηκÎÅÍ´Â Àß Èí¼öµÈ´Ù.
|
| Biotransformation |
Dibucaine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Primarily hepatic.
|
| Toxicity |
Dibucaine¿¡ ´ëÇÑ Toxicity Á¤º¸ Subcutaneous LD50 in rat is 27 mg/kg. Symptoms of overdose include convulsions, hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest.
|
| Drug Interactions |
Dibucaine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Methotrexate The NSAID increases the effect and toxicity of methotrexateLithium The NSAID increases serum levels of lithiumAcenocoumarol The NSAID increases the anticoagulant effect
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Dibucaine¿¡ ´ëÇÑ Description Á¤º¸ A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006)
|
| Dosage Form |
Dibucaine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Ointment Rectal
|
| Drug Category |
Dibucaine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anesthetics, Local
|
| Smiles String Canonical |
Dibucaine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC
|
| Smiles String Isomeric |
Dibucaine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC
|
| InChI Identifier |
Dibucaine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24)/f/h21H
|
| Chemical IUPAC Name |
Dibucaine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-butoxy-N-(2-diethylaminoethyl)quinoline-4-carboxamide
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2016-05-10
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|